Are We Abandoning the Search for Acute Stroke Therapies?

Stroke: April 4, 2013

The pharmaceutical industry is in the doldrums. Food and Drug Administration drug approvals per year are falling steadily,1 and the costs of drug development are steadily increasing.2However, although neuroscience as a whole may not be delivering the returns on investment we would like, the state of stroke medicine has never been better. Read more